Corvus Pharmaceuticals (CRVS) Projected to Post Quarterly Earnings on Thursday

Corvus Pharmaceuticals (NASDAQ:CRVS) is expected to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:00 PM ET.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, March 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Up 2.6%

Shares of NASDAQ:CRVS traded up $0.41 on Wednesday, reaching $16.11. 101,188 shares of the company’s stock were exchanged, compared to its average volume of 2,799,912. The business’s 50-day moving average is $15.62 and its two-hundred day moving average is $12.72. Corvus Pharmaceuticals has a fifty-two week low of $3.16 and a fifty-two week high of $26.95. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -32.13 and a beta of 0.94.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Oppenheimer reiterated an “outperform” rating and set a $33.00 price objective (up from $32.00) on shares of Corvus Pharmaceuticals in a research note on Friday, March 13th. Jefferies Financial Group lifted their target price on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. HC Wainwright upped their target price on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. The Goldman Sachs Group began coverage on Corvus Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Weiss Ratings raised Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $33.33.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Large investors have recently made changes to their positions in the company. Orbimed Advisors LLC raised its holdings in shares of Corvus Pharmaceuticals by 3.2% during the second quarter. Orbimed Advisors LLC now owns 7,165,006 shares of the company’s stock valued at $28,660,000 after buying an additional 221,352 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Corvus Pharmaceuticals by 5.8% during the third quarter. Vanguard Group Inc. now owns 3,471,925 shares of the company’s stock worth $25,588,000 after buying an additional 191,216 shares during the period. State Street Corp grew its holdings in Corvus Pharmaceuticals by 177.1% in the 4th quarter. State Street Corp now owns 2,788,223 shares of the company’s stock worth $21,469,000 after buying an additional 1,781,904 shares in the last quarter. MPM Bioimpact LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $21,126,000. Finally, Geode Capital Management LLC increased its position in Corvus Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,473,026 shares of the company’s stock valued at $11,345,000 after acquiring an additional 16,498 shares during the period. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.